Literature DB >> 17148995

Tumor volume as outcome determinant in patients treated with chemoradiation for locally advanced esophageal cancer.

Gilles Créhange1, Mathieu Bosset, Fabrice Lorchel, Lorchel Fabrice, Joëlle Buffet-Miny, Jean Luc Dumas, Mariette Mercier, Marc Puyraveau, Philippe Maingon, Jean François Bosset.   

Abstract

OBJECTIVE: The currently used tumor-node metastasis (TNM) staging method is generally not applicable to patients with unresectable esophageal carcinomas. There is a need for both an efficient, easy-to-perform clinical classification and for identification of pretherapeutic prognostic factors that would be useful for oncologists, one of which is tumor volume.
METHODS: Records of 148 patients, admitted to hospital during the period January 1993 to December 2001, were evaluated retrospectively. Median age was 65.7 years (range, 35.5-85.5 years). Most patients had SCC (84.5%). Using the computed tomography (CT) scan classification, tumors were recorded as follows: 1 T1, 42 T2, 93 T3, 6 T4, 2 Nx, 72 N0, 74 N1. Tumor volume from the CT scans was determined as the sum of 2 opposed truncated cones. Median tumor volume was 57.5 cm3 (range, 0.6-288 cm3).
RESULTS: Median follow-up was 15.1 month (range, 0.3-82.8 months). Survival rates at 1, 2, and 3 years were 42.5%, 21.6%, and 8%, respectively. Prognostic factors identified by univariate analysis were: dysphagia grade > or =2, other histology than squamous cell, tumor location below the carina, age <65 years and tumor volume > or =100 cm3. Prognostic factors identified with multivariate analysis were: dysphagia grade > or =2 (P = 0.013), weight loss > or =10% (P = 0.047), tumor location below the carina (P = 0.002), and tumor volume > or =100 cm3 (P = 0.041).
CONCLUSIONS: For patients that the TNM staging system is not applicable, tumor volume is a new powerful determinant of survival. Further clinical trials need to be carried out to validate this prospectively.

Entities:  

Mesh:

Year:  2006        PMID: 17148995     DOI: 10.1097/01.coc.0000242346.25229.48

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  16 in total

1.  Prognostic significance of endoluminal ultrasound-defined disease length and tumor volume (EDTV) for patients with the diagnosis of esophageal cancer.

Authors:  Christopher P Twine; S Ashley Roberts; Wyn G Lewis; B Vicki Dave; Claire E Rawlinson; David Chan; Mark Robinson; Tom D Crosby
Journal:  Surg Endosc       Date:  2010-04       Impact factor: 4.584

2.  Oesophageal cancer: assessment of tumour response to chemoradiotherapy with tridimensional CT.

Authors:  Rita Alfieri; Giovanna Pintacuda; Matteo Cagol; Tommaso Occhipinti; Ivan Capraro; Marco Scarpa; Gianpietro Zanchettin; Francesco Cavallin; Mauro Michelotto; Luciano Giacomelli; Ermanno Ancona; Carlo Castoro
Journal:  Radiol Med       Date:  2014-10-30       Impact factor: 3.469

3.  Tumour size of resectable oesophageal squamous cell carcinoma measured with multidetector computed tomography for predicting regional lymph node metastasis and N stage.

Authors:  Hang Li; Tian-wu Chen; Zhen-lin Li; Xiao-ming Zhang; Xiao-li Chen; Li-ying Wang; Li Zhou; Rui Li; Chun-ping Li; Xiao-hua Huang
Journal:  Eur Radiol       Date:  2012-06-01       Impact factor: 5.315

4.  The Significant Role of Tumor Volume on the Surgical Approach Choice, Surgical Complexity, and Postoperative Complications in Renal Cell Carcinoma With Venous Tumor Thrombus From a Large Chinese Center Experience.

Authors:  Qais Baheen; Zhuo Liu; Yichang Hao; Rejean R R Sawh; Yuxuan Li; Xun Zhao; Peng Hong; Zonglong Wu; Lulin Ma
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

5.  Longitudinal volume analysis from computed tomography: Reproducibility using adrenal glands as surrogate tumors.

Authors:  Nicolas D Prionas; Marijo A Gillen; John M Boone
Journal:  J Med Phys       Date:  2010-07

6.  Variation by stage in the effects of prediagnosis weight loss on mortality in a prospective cohort of esophageal cancer patients.

Authors:  S Shen; J L Araujo; N K Altorki; J R Sonett; A Rodriguez; K Sungur-Stasik; C F Spinelli; A I Neugut; J A Abrams
Journal:  Dis Esophagus       Date:  2017-09-01       Impact factor: 3.429

7.  Pretreatment metabolic tumour volume is predictive of disease-free survival and overall survival in patients with oesophageal squamous cell carcinoma.

Authors:  Charles Lemarignier; Frédéric Di Fiore; Charline Marre; Sébastien Hapdey; Romain Modzelewski; Pierrick Gouel; Pierre Michel; Bernard Dubray; Pierre Vera
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-07-19       Impact factor: 9.236

8.  Tumour volume of resectable oesophageal squamous cell carcinoma measured with MRI correlates well with T category and lymphatic metastasis.

Authors:  Lan Wu; Jing Ou; Tian-Wu Chen; Rui Li; Xiao-Ming Zhang; Yan-Li Chen; Yu Jiang; Jian-Qiong Yang; Jin-Ming Cao
Journal:  Eur Radiol       Date:  2018-05-14       Impact factor: 5.315

9.  Gross tumor volume is the prognostic factor for squamous cell esophageal cancer patients treated with definitive radiotherapy.

Authors:  Yun Chen; Zhen Zhang; Guoliang Jiang; Kuaile Zhao
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

10.  Radiomics approach for preoperative identification of stages I-II and III-IV of esophageal cancer.

Authors:  Lei Wu; Cong Wang; Xianzheng Tan; Zixuan Cheng; Ke Zhao; Lifen Yan; Yanli Liang; Zaiyi Liu; Changhong Liang
Journal:  Chin J Cancer Res       Date:  2018-08       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.